drugset / Trial / NCT01386346
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
Phase 1
Completed
12 enrolled
Weill Medical College of Cornell University
Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see whether giving azacitidine before each cycle of chemotherapy prior to surgery is safe.
Timeline
- Start
- 2011-06
- Primary completion
- 2014-08
- Completion
- 2018-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 50 mg/m2 | Subcutaneous |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Background | Capecitabine | Small molecule | 625 mg/m2 | Oral |
| Background | Epirubicin | Small molecule | 50 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |